98%
921
2 minutes
20
Schizophrenia is a prevalent neurodevelopmental psychiatric disorder that remains inadequately managed by current treatments, highlighting the urgent need for new pharmacotherapeutic approaches. Nutraceuticals have gained attention due to their favorable safety and multifaceted pharmacological benefits. Among these, scoparone exhibits a well-documented neuropsychopharmacological profile; however, its potential therapeutic effects on schizophrenia remain unclear and warrant further investigation. Consequently, this study aimed to evaluate the influence of scoparone treatment on MK-801-induced schizophrenia-like behaviors in C57BL/6 mice. C57BL/6 mice were injected with MK-801 (0.6 mg/kg/day, i.p.) for 7 consecutive days to induce schizophrenia. Mice were treated with scoparone (25 mg/kg/day, i.p.) 2 h after the MK-801 administration. Interestingly, scoparone attenuated MK-801-induced positive, negative, and cognitive symptoms of schizophrenia, as demonstrated in behavioral tests. Furthermore, it hindered MK-801-induced histopathological changes in the hippocampus. Importantly, the biochemical analysis shed light on the ability of scoparone to activate the neuroprotective silent mating type information regulation 2 homolog 1/peroxisome proliferator-activated receptor-γ coactivator-1-α/mitochondrial transcription factor A (SIRT1/PGC-1α/TFAM) signaling pathway, thereby regulating mitochondrial homeostasis. Concisely, PGC-1α activation hinders dynamin-related protein 1 (Drp1) levels, restricting mitochondrial fission. Conversely, it augments the fusion of adjacent mitochondria by boosting Mitofusin 2 (MFN2) and protein optic atrophy 1 (OPA1) levels. Moreover, it enhanced mitophagy for selective removal of damaged mitochondria. In conclusion, this study underscores scoparone's beneficial effect in MK-801-induced schizophrenia-like behaviors via SIRT1 activation, which manipulates multiple axes involved in the pathophysiology of schizophrenia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejphar.2025.177981 | DOI Listing |
Eur J Pharmacol
October 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy Cairo University, Cairo, 11562, Egypt.
Schizophrenia is a prevalent neurodevelopmental psychiatric disorder that remains inadequately managed by current treatments, highlighting the urgent need for new pharmacotherapeutic approaches. Nutraceuticals have gained attention due to their favorable safety and multifaceted pharmacological benefits. Among these, scoparone exhibits a well-documented neuropsychopharmacological profile; however, its potential therapeutic effects on schizophrenia remain unclear and warrant further investigation.
View Article and Find Full Text PDFCurr Med Sci
August 2025
General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China.
Objective: Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive, affective, and behavioral abnormalities. Existing treatments have yielded limited effects on improving cognitive function. Recent studies have identified the abnormal differentiation of hippocampal neural stem cells (NSCs), neuronal loss, and dysregulated proliferation of astrocytes as significant pathological mechanisms contributing to the symptoms of schizophrenia.
View Article and Find Full Text PDFSchizophr Bull
April 2025
Department of Psychiatry, Taipei Veterans General Hospital, Taipei 112201, Taiwan.
Background And Hypothesis: Abdominal low-intensity pulsed ultrasound (LIPUS) stimulation has potential as a novel therapeutic strategy against neuroinflammation via inhibition of inflammatory responses in the colon. This study aimed to evaluate whether abdominal LIPUS could alleviate MK-801-induced schizophrenia-like negative symptoms through gut-brain communication.
Study Design: Rats administered with MK-801 were treated daily for 5 days with either LIPUS or Lactobacillus plantarum PS128, while another group of MK-801-administered rats received no treatment.
Schizophrenia (Heidelb)
March 2025
Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, School of Mental Health, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, P.R. China.
Although MK801-induced NMDA receptor (NMDAR) hypofunction mimics schizophrenia symptoms, the exact factors causing NMDAR inhibition are unknown. Unexpectedly, external stress elicits formaldehyde (FA) generation; FA can induce depression and cognitive impairments by blocking NMDARs. This study explores using FA injection to establish a schizophrenia-like model in mice.
View Article and Find Full Text PDFInt Immunopharmacol
April 2025
Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan 430060, China; Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan 430060, China. Electronic address:
The management of cognitive impairments in schizophrenia presents a considerable challenge, with a strong association between neuroinflammation and its progression. Urolithin A (UA) demonstrates important anti-inflammatory properties in multiple neurological disease models, contributing to the enhancement of cognitive deficits. However, it remains uncertain if UA can produce comparable neuroregulatory effects in female rat models of schizophrenia.
View Article and Find Full Text PDF